UP0.F

Ultragenyx Pharmaceutical Inc.
FrankfurtEUREQUITY Healthcare DELAYED
Last price
22.35
▲ 0.80 (3.71%)
MARKET ·

Price

1D H L Range Vol
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
22.35
Prev close
21.55
Day high
22.35
Day low
22.35
Volume
229
Market cap
$2.20B
P/E (TTM)
52W range
15.90 – 34.00

Day trading desk

Current session · delayed
Gap from prior close
+3.71%
Prior close 21.55
VWAP
Relative volume
0.00×
Quiet session
Session range
22.35 – 22.35
Position in range
ATR (14D)
1.04
4.64% of price
Prior day high
21.55
PDH
Prior day low
21.55
PDL
Bid / ask spread
Quote not published
Session volume
Avg 5

VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.

Trailing performance

Price return · vs SPY
Returnvs SPY
1W
-2.40% -1.1%
1M
-5.01% -8.3%
3M
+13.42% +11.1%
6M
+17.63% +5.8%
YTD
+31.47% +19.6%
1Y
-11.31% -31.4%
3Y
-33.48% -108.4%
5Y
-74.16%

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Unusual options activity

Account required
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
Free account required

Contracts trading at or above their open interest, ranked by notional and where the print landed.

Free account

5 more panels on UP0.F open with an account.

Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.

Insider net activity

6m · Form 4 rollup
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
Net transactions
0
Buys less sells
Sell : buy shares
Not enough filings
Insider-held shares
3.38M
Total on file

Insider transactions

Account required
DateInsiderAction SharesValueHeld
Aug 3, 26
PARSCHAUER KARAH HERDMAN
Officer
SELL 1.90K $47.35K Direct
Aug 3, 26
HORN HOWARD
Chief Financial Officer
SELL 4.70K $117.02K Direct
Jul 1, 26
HORN HOWARD
Chief Financial Officer
SELL 4.70K $155.65K Direct
Jun 15, 26
SANDERS CORAZON CORSEE D
Director
SELL 2.00K $50.10K Direct
Jun 15, 26
PARSCHAUER KARAH HERDMAN
Officer
SELL 1.90K $46.75K Direct
Jun 1, 26
HORN HOWARD
Chief Financial Officer
SELL 4.65K $110.60K Direct
May 18, 26
SULIMAN SHEHNAAZ
Director
SELL 5.74K $144.19K Direct
May 14, 26
SULIMAN SHEHNAAZ
Director
STOCK 7.75K $0 Direct
May 14, 26
SANDERS CORAZON CORSEE D
Director
STOCK 7.75K $0 Direct
May 14, 26
RAY AMRIT
Director
STOCK 7.75K $0 Direct
May 14, 26
DUNSIRE DEBORAH
Director
STOCK 7.75K $0 Direct
May 14, 26
NARACHI MICHAEL A
Director
STOCK 7.75K $0 Direct
May 14, 26
FUST MATTHEW K.
Director
STOCK 7.75K $0 Direct
May 14, 26
WELCH DANIEL G
Director
STOCK 7.75K $0 Direct
What this is, and what it is not

These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.

A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.

This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.

Free account required

Officer and director trades in their own stock, straight from Form 4 filings.

Insider holders

10 reporting
NameRelationShares heldLatest
CROMBEZ ERIC M.D.
Officer 111.19K Sale
HARRIS ERIK
Officer 118.41K Stock Award(Grant)
HORN HOWARD
Chief Financial Officer 96.30K Sale
HUANG DENNIS KARL
Chief Technology Officer 147.84K Stock Award(Grant)
HUIZENGA THEODORE ALAN
Officer 68.91K Stock Award(Grant)
KAKKIS EMIL D
Chief Executive Officer 2.89M Stock Award(Grant)
KASSBERG THOMAS RICHARD
Chairman of the Board 264.73K Sale
PARSCHAUER KARAH HERDMAN
Officer 92.56K Sale
PINION JOHN RICHARD
Officer 133.14K Stock Award(Grant)
WELCH DANIEL G
Director 40.44K Stock Award(Grant)

Fundamentals

TTM · reported
Market cap$2.20B
Enterprise value$3.04B
Revenue (TTM)$717.00M
Gross profit$-149.00M
EBITDA$-465.00M
Net income$-586.00M
EPS (TTM)$-4.99
Free cash flow$-179.83M
Total cash$292.00M
Total debt$1.20B
Book value / share$-2.11
Shares outstanding98.59M
Float80.42M
Short % of float
Dividend yield
Beta (5Y)0.31

Valuation & profitability ratios

Account required
Trailing P/E
Forward P/E-3.89
PEG ratio
Price / sales
Price / book
EV / revenue4.23
EV / EBITDA-6.53
Gross margin-20.78%
Operating margin-35.05%
Profit margin-81.73%
Return on equity
Return on assets-24.22%
Debt / equity
Current ratio1.73
Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Financial statements

As reported · 4 years · 6 quarters
Blank means not reported, not zero
Line item2025202420232022YoY
Total revenue $673.00M$560.00M$434.00M$363.33M +20.2%
Operating revenue $673.00M$560.00M$434.00M$363.33M +20.2%
Cost of revenue $109.00M$77.00M$45.00M$28.32M +41.6%
Gross profit $564.00M$483.00M$389.00M$335.01M +16.8%
Research & development $750.00M$698.00M$648.00M$705.79M +7.4%
Selling, general & admin $349.00M$321.00M$310.00M$278.14M +8.7%
Total operating expense $1.10B$1.02B$958.00M$983.93M +7.9%
Operating income -$535.00M-$536.00M-$569.00M-$648.92M +0.2%
Net interest income -$37.00M-$26.00M-$39.00M-$31.94M -42.3%
Pre-tax income -$571.00M-$567.00M-$609.00M-$701.73M -0.7%
Tax provision $4.00M$2.00M-$2.00M$5.70M +100.0%
Net income -$575.00M-$569.00M-$607.00M-$707.42M -1.1%
Net income to common -$575.00M-$569.00M-$607.00M-$707.42M -1.1%
Basic EPS -5.83-6.29-8.25-10.12 +7.3%
Diluted EPS -5.83-6.29-8.25-10.12 +7.3%
EBIT -$509.00M-$504.00M-$543.00M-$658.71M -1.0%
EBITDA -$474.00M-$468.00M-$517.00M-$640.49M -1.3%
Basic shares 98.60M90.54M73.54M69.91M +8.9%
Diluted shares 98.60M90.54M73.54M69.91M +8.9%

Options analytics

Account required
Put / call volume
Put / call open interest
Positioning, not flow
Max pain
ATM implied vol
Nearest strike to spot
Skew (10% OTM)
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
Heaviest put OI

Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.

Free account required

Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.

Earnings

History & consensus estimates
Forward consensus
PeriodEPSAnalystsRevenueGrowth
Current quarter $182.60M +14.2%
Next quarter $227.39M +9.9%
Current year $761.87M +13.2%
Next year $1.01B +32.8%

Analyst targets & ownership

Account required
Mean target
High target
Low target
Implied upside
Analyst count
ConsensusNONE
Strong buy / Buy— / —
Hold
Sell / Strong sell— / —
Held by insiders3.44%
Held by institutions111.88%
Institutions holding435
Free account required

Price targets, consensus spread, insider and institutional ownership.

Moving averages & technicals

Computed from 2Y daily closes
SMA 10
22.85
-2.18% from price
SMA 20
22.53
-0.80% from price
SMA 50
24.78
-9.82% from price
SMA 100
22.56
-0.95% from price
SMA 200
22.55
-0.87% from price
EMA 12
22.78
-1.90% from price
EMA 26
23.26
-3.92% from price
EMA 50
23.43
-4.59% from price
RSI (14)
46.3
Neutral
MACD (12,26,9)
-0.48
Hist 0.10
ATR (14)
1.04
4.64% of price
Realised vol 30D
79.3%
Annualised
Bollinger upper
24.32
20, 2σ
Bollinger lower
20.74
20, 2σ
50 / 200 cross
Golden
24.78 vs 22.55
Trend bias
Below 200
-0.87%

Options chain

Account required
Expiry
Spot 22.35
Calls
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Puts
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Risk profile

Daily returns · 1Y window
Beta vs SPY
0.59
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
79.3%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-50.9%
Peak to trough
Max drawdown 5Y
-81.6%
Peak to trough
ATR 14
1.04
4.64% of price
Beta (reported)
0.31
5Y monthly, from filing

Rating changes

184 on file
DateFirm ActionFromTo
Oct 22, 24 Cantor Fitzgerald MAINTAINED Overweight Overweight
Oct 21, 24 TD Cowen MAINTAINED Buy Buy
Oct 1, 24 Cantor Fitzgerald MAINTAINED Overweight Overweight
Sep 26, 24 RBC Capital MAINTAINED Outperform Outperform
Sep 20, 24 Cantor Fitzgerald MAINTAINED Overweight Overweight
Sep 16, 24 Cantor Fitzgerald MAINTAINED Overweight Overweight
Aug 5, 24 Barclays MAINTAINED Overweight Overweight
Aug 2, 24 Wells Fargo MAINTAINED Overweight Overweight
Aug 2, 24 Goldman Sachs MAINTAINED Buy Buy
Aug 2, 24 Cantor Fitzgerald MAINTAINED Overweight Overweight
Aug 2, 24 Wedbush MAINTAINED Neutral Neutral
Jul 23, 24 Canaccord Genuity MAINTAINED Buy Buy

Dividends & splits

Declared · from the issuer
Forward rate
Forward yield
5-year avg yield
Payout ratio0.00%
Ex-dividend date
Next pay date
Last split1:3.1345
Split dateJan 17, 2014

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.